Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects

References

• MishraMK. Medicinal plants: role in treatment of diabetes. Int J Adv Sci Res Manag. 2019;S1:139–153.
   Google Scholar
• SaeediP, PetersohnI, SalpeaP, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.10784331518657
   PubMed Web of Science ®Google Scholar
• ShahMA, JakkawanpitakC, SermwittayawongD, PanichayupakaranantP. Rhinacanthins-rich extract enhances glucose uptake and inhibits adipogenesis in 3T3-L1 adipocytes and L6 myotubes. Pharmacogn Mag. 2017;13(Suppl 4):S817.
   Google Scholar
• AhrenB. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21(4):517–533. doi:10.1016/j.beem.2007.07.00518054733
   PubMed Web of Science ®Google Scholar
• HongSM, ParkCY, HwangDM, et al. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: a 24-week randomized, controlled trial with open label extension. Diabetes Obes Metab. 2017;19(5):654–663.28058750
   PubMed Web of Science ®Google Scholar
• ParkJ, ParkSW, YoonKH, et al. Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. Diabetes Obes Metab. 2017;19(12):1681–1687. doi:10.1111/dom.1298728448688
   PubMed Web of Science ®Google Scholar
• GuN, ParkMK, KimTE, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014;8:1709–1721. doi:10.2147/DDDT.S65678
   PubMed Web of Science ®Google Scholar
• KimHJ, KwakWY, MinJP, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011;21(12):3809–3812. doi:10.1016/j.bmcl.2011.04.02921570283
   PubMed Web of Science ®Google Scholar
• OhE, ChoiC, KimC, et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. J Clin Pharm Ther. 2017;42(6):689–694. doi:10.1111/jcpt.1260428806472
   PubMed Web of Science ®Google Scholar
• ChanJC, MalikV, JiaW, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–2140. doi:10.1001/jama.2009.72619470990
   PubMed Web of Science ®Google Scholar
• LangtryHD, BalfourJA. Glimepiride. Drugs. 1998;55(4):563–587. doi:10.2165/00003495-199855040-000079561345
   PubMed Web of Science ®Google Scholar
• HottaN. A new perspective on the biguanide, metformin therapy in type 2 diabetes and lactic acidosis. J Diabetes Investig. 2019;10(4):906–908. doi:10.1111/jdi.13090
   PubMed Web of Science ®Google Scholar
• KoS-H, HurK-Y, RheeSY, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes Metab J. 2017;41(5):337–348. doi:10.4093/dmj.2017.41.5.33729086531
   PubMed Web of Science ®Google Scholar
• McGuireH, LongsonD, AdlerA, FarmerA, LewinI. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ. 2016;353:i1575. doi:10.1136/bmj.i157527052837
   PubMed Web of Science ®Google Scholar
• SerraD, HeY, BullockJ, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Int J Clin Pharmacol Ther. 2008;46(7):349–364. doi:10.5414/CPP4634918793589
   PubMed Web of Science ®Google Scholar
• FriedrichC, MetzmannK, RoseP, MattheusM, PinnettiS, WoerleHJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35(1):A33–A42. doi:10.1016/j.clinthera.2012.12.00223328275
   PubMed Web of Science ®Google Scholar
• KarimA, ZhaoZ, SlaterM, BradfordD, SchusterJ, LaurentA. Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation. J Clin Pharmacol. 2007;47(7):806–816. doi:10.1177/009127000730095417463215
   PubMed Web of Science ®Google Scholar
• NiemiM, BackmanJT, NeuvonenM, LaitilaJ, NeuvonenPJ, KivistöKT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;69(4):194–200. doi:10.1067/mcp.2001.11422911309547
   PubMed Web of Science ®Google Scholar
• MachaS, MattheusM, PinnettiS, SemanL, WoerleHJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. J Diabetes Res Clin Metab. 2012;1(1):14. doi:10.7243/2050-0866-1-14
   Google Scholar
• ParkJW, KimKA, ChoiYJ, YoonSH, ParkJY. Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. J Clin Pharm Ther. 2019;44(5):720–725. doi:10.1111/jcpt.1284831094010
   PubMed Web of Science ®Google Scholar
• ChoiHY, KimYH, KimMJ, et al. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs R D. 2014;14(3):165–176. doi:10.1007/s40268-014-0054-824962635
   PubMedGoogle Scholar
• TripathiAS, TimiriAK, MazumderPM, ChandewarA. Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies. J Mol Model. 2015;21(10):276. doi:10.1007/s00894-015-2823-x26428531
   PubMed Web of Science ®Google Scholar
• RyanAS, EganJM, HabenerJF, ElahiD. Insulinotropic hormone glucagon-like peptide-1-(7–37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab. 1998;83(7):2399–2404.9661618
   PubMed Web of Science ®Google Scholar
• NauckMA, HeimesaatMM, OrskovC, HolstJJ, EbertR, CreutzfeldtW. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307. doi:10.1172/JCI1161868423228
   PubMed Web of Science ®Google Scholar
• HolstJJ, GromadaJ. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199–E206. doi:10.1152/ajpendo.00545.200315271645
   PubMed Web of Science ®Google Scholar
• JungCH, ParkCY, AhnKJ, et al. A randomized, double-blind, placebo-controlled, Phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev. 2015;31(3):295–306. doi:10.1002/dmrr.261325362864
   PubMed Web of Science ®Google Scholar
• RheeSJ, ChoiY, LeeS, et al. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. Drug Des Devel Ther. 2016;10:2525–2534. doi:10.2147/DDDT.S110712
   PubMed Web of Science ®Google Scholar
• DunningB, FoleyJ, AhrénB. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48(9):1700–1713. doi:10.1007/s00125-005-1878-016132964
   PubMed Web of Science ®Google Scholar